BK virus cystitis is known to occur following hematopoietic stem cell transplant (HSCT), but few cases exist in the literature following lung transplant. Because of the rarity of this presentation, patients may have missed diagnoses and prescribed ineffective treatments. We present our case of an atypical presentation of BK virus cystitis appearing as bladder carcinoma in situ in a lung transplant patient.Chronic liver disease caused by hepatitis B virus (HBV) remains an important health issue. Though there are effective HBV-polymerase inhibitors (e.g., lamivudine), their prolonged use leads to emergence of drug-resistant (polymerase mutant) strains. Several herbal formulations and phytochemicals have been therefore, reported as potential anti-HBV agents with no sign of resistance in experimental and clinical settings. In this study, we assessed the anti-HBV as well as hepatoprotective salutations of solanopubamine, a rare alkaloid isolated from S. schimperianum. In cultured HepG2.2.15 cells, solanopubamine showed marked anti-HBV activity in a time and dose-dependent manner. Solanopubamine (30 μM) efficiently inhibited HBsAg and HBeAg expressions by 66.5%, 70.5%, respectively as compared to 82.5% and 86.5% respective inhibition by lamivudine (2 μM) at day 5.

Molecular docking analyses of solanopubamine revealed formations of stable complexes with lamivudine-sensitive as well as lamivudine-resistant polymerase through interactions of catalytic ‘YMDD/YIDD’ motif residues. Moreover, solanopubamine attenuated DCFH-induced oxidative and apoptotic damage and restored HepG2 cell viability by 28.5%, and downregulated caspase-3/7 activations by 33%. Further docking analyses of solanopubamine showed formation of stable complexes with caspase-3/7. Taken together, our data demonstrates promising anti-HBV and anti-hepatotoxic therapeutic potential of solanopubamine, and warrants further molecular and pharmacological studies.

Posttransplant lymphoma, classified as posttransplant lymphoproliferative disorder (PTLD) in the majority of cases, affects 1% to 3% of kidney transplant recipients and is associated with significant morbidity and mortality. The clinical presentation is variable, ranging from 1 site to multiorgan disease. Renal allograft involvement is seen in as many as 13% of recipients with histologic features of predominantly monomorphic or polymorphic B-cell proliferation. Posttransplant lymphoma presenting as plasmacytic infiltration confined to an allograft has been described in few cases. We present a rare case of Epstein Barr virus (EBV)–negative, lymphoplasmacytic proliferation limited to an allograft incidentally found on the protocol biopsy.

Visit for more related articles at Rare Disorders: Diagnosis & Therapy

Kindly submit your article through Editorial Tracking or through raredisord@emedicalscience.com

With Regards
Sofia
Journal Co-ordinator
Journal of Rare Disorders: Diagnosis & Therapy